Protein kinase A as a biological target in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 1, 2009, Pages 83-92

  Naviglio, Silvio ^a   Caraglia, Michele ^a   Abbruzzese, Alberto ^a   Chiosi, Emilio ^a   Di Gesto, Davide ^a   Marra, Monica ^a   Romano, Maria ^a   Sorrentino, Annunziata ^a   Sorvillo, Luca ^a   Spina, Annamaria ^a   Illiano, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

cAMP; cAMP analogs; CREB; Gene therapy; PKA

Indexed keywords

6 [3 (DIMETHYLAMINO)PROPIONYL]FORSKOLIN; 8 CHLOROADENOSINE 3',5' MONOPHOSPHATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORSKOLIN; FORSKOLIN DERIVATIVE; GENE EXPRESSION MODULATOR 231; ISOENZYME; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE; ROLIPRAM; SILDENAFIL; TUMOR MARKER; UNCLASSIFIED DRUG; CYCLIC AMP; PROTEIN KINASE INHIBITOR;

ACUTE HEART FAILURE; ANTISENSE THERAPY; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; COLON CANCER; DEPRESSION; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME REGULATION; ERECTILE DYSFUNCTION; FIBROSARCOMA; HEART FAILURE; HUMAN; LEUKEMIA; LUNG CANCER; MALIGNANT TRANSFORMATION; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT MONITORING; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 61449309335     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802602349     Document Type: Review

References (89)

1. Robison GA, Butcher RW, Sutherland EW. Cyclic AMP. Annu Rev Biochem 1968; 37 : 149-174
2. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001 ; 41 : 145-174
3. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007 ; 100 (3): 309-327
4. Tasken K, Skalhegg BS, Tasken KA, et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997 ; 31 : 191-204
5. De Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998 ; 396 : 474-477
6. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002 ; 12 (6): 258-266 • The authors describe the capacity of cAMP for either positive or negative regulation of the ERK cascade accounting for many of the cell-type-specific actions of cAMP on cell proliferation. There are several specific mechanisms involved in the inhibition or activation of ERKs by cAMP. One of these mechanisms involves the activation of the GTPase Ras-related protein-1 (Rap1), which can activate or inhibit ERK signaling in a cell-specific manner.
7. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000 ; 5 : D678 -93
8. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 2002 ; 3 (9): 710-718
9. Naviglio S, Pagano M, Romano M, Sorrentino, et al. Adenylate cyclase regulation via proteasome-mediated modulation of G α levels. Cell Signal 2004 ; 16 (11): 1229-1237 • The authors describe a novel mechanism for adenylate cyclase activity regulation by proteasome pathway, identifying a s protein as a novel proteasome substrate in mammalian cells.
10. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes Science 2002 ; 295 : 1711-1715
11. Willoughby D, Cooper DM. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 2007; 87 (3): 965-1010
12. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997 ; 387 : 569-572
13. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 2007 ; 19 : 192-198 • The data presented in this paper contribute to defining A-kinase anchoring proteins (AKAPs) role in cAMP signaling; AKAPs tether PKA to specific subcellular sites, thereby focusing its activity toward relevant substrates.
14. Kim C, Cheng CY, Saldanha SA, et al. PKA-I holenzyme structure reveals mechanism for cAMP-dependent activation. Cell 2007 ; 130 : 1032-1043 •• In this paper structural insights, combined with mutagenesis results, provide a molecular mechanism for the ordered and cooperative activation of PKA by cAMP.
15. Wu J, Brown SH,avon Daake S, et al. PKA type II α holoenzyme reveals a combinatorial strategy for isoform diversity. Science 2007 ; 318 : 274-279 •• This study demonstrates the conserved and isoform-specific features of RI and RII and also provides a new paradigm for designing isoform-specific activators or antagonists for PKA.
16. Gold MG, Lygren B, Dokurno P, et al. Molecular basis of AKAP specifi city for PKA regulatory subunits. Mol Cell 2006 ; 24 : 383-395
17. Su Y, Dostmann WR, Herberg FW, et al. Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. Science 1995 ; 269 : 807-813
18. Diller TC, Madhusudan, Xuong NH, et al. Molecular basis for regulatory subunit diversity in cAMP-dependent protein kinase: crystal structure of the type II beta regulatory subunit. Structure 2001 ; 9 : 73-82
19. Kim C, Xuong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (Rl α ) subunits of PKA. Science 2005 ; 307 : 690-696
20. Knighton DR, Zheng JH, Ten LF, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991 ; 253 : 407-414
21. Wirtenberger M, Tchatchou S, Hemminki K, et al. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 2006 ; 27 : 593-598
22. Wirtenberger M, Schmutzhard J, Hemminki K, et al. The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis 2007 ; 28 : 423-426
23. Sharma S, Qian F, Keitz B, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol 2005 ; 99 : 183-188
24. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 2008 ; 20 (3): 460-466
25. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001 ; 2 : 599-609
26. Siu YT, Jin DY. CREB - a real culprit in oncogenesis. Febs J 2007 ; 274 : 3224-3232 • This minireview summarizes the different lines of existing evidence that support a direct role of calcium response element binding protein (CREB) in oncogenesis. Regulated activation of CREB has a significant effect on cellular growth, proliferation and survival. To overturn the cellular control of these processes, tumor cells have developed various mechanisms to achieve constitutive activation of CREB, (gene amplification, chromosome translocation, interaction with viral oncoproteins, and inactivation of tumor suppressor genes). These mechanisms converge on the phosphorylation of CREB and/or the activation of transducer of regulated CREB activity (TORC) coactivators to effect uncontrolled proliferation of cells.
27. McGarrity TJ, Amos C. Peutz-Jeghers syndrome: clinicopathology and molecular alterations. Cell Mol Life Sci 2006 ; 63 : 2135-2144
28. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007 ; 26 (22): 3227-3239
29. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001 ; 410 : 37-40
30. Sebastian S, Settleman J, Reshkin SJ, et al. The complexity of targeting EGFR signaling in cancer: From expression to turnover. Biochim Biophys Acta 2006 ; 1766 : 120-139
31. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001 ; 22 : 153-183
32. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer. Front Biosci 2008 ; 13 : 1857-1865
33. Castoria G, Migliaccio A, D'Amato L, et al. Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci 2008 ; 13 : 1318-1327
34. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 2005 ; 202 (2): 323-335
35. Ciardiello F, Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 1998 ; 4 : 821-828
36. Naviglio S, Spina A, Marra M, et al. Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN- α in human epidermoid cancer cells. J interferon Cytokine Res 2007 ; 27 (2): 129-136
37. Caraglia M, Marra M, Viscomi C, et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon- α through the inhibition of multiple survival pathways. Int J Cancer 2008 ; 121 (10): 2317 -30; erratum in 122(8): 1922
38. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003 ; 9 (4): 1566-1572
39. Cho-Chung YS, Pepe S, Budillon A, et al. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol 1995 ; 21 : 33-61
40. Rosenberg D, Groussin L, Bertagna X, et al. cAMP pathway alterations from the cell surface to the nucleus in adrenocortical tumors. Endocr Res 2002 ; 28 : 765-775
41. Rivas M. & Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 2003 ; 213 : 31-45
42. Mantovani G, Lania AG, Bondioni S, et al. Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. Exp Cell Res 2008 ; 314 (1): 123-130
43. Bradbury AW, Carter DC, Miller WR, et al. Protein kinase A (PKA) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994 ; 69 : 738-742
44. McDaid HM, Cairns MT, Atkinson RJ, et al. Increased expression of the RI subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999 ; 79 : 933-939
45. Miller WR. Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 2002 ; 968 : 37-48
46. Mantovani G, Bondioni S, Lania AG, et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 2008 ; 27 (13): 1834-1843 • This study evaluates the effects of selective activation of the different PKA regulatory subunits type RI a and type RII a on melanocyte proliferation. This study first reports that human melanomas are characterized by a high RI:RII ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.
47. Cho-Chung YS. Antisense protein kinase A RI α -induced tumor reversion: portrait of a microarray. Biochim Biophys Acta 2004 ; 1697 : 71-79
48. Tortora G, Budillon A, Yokozaki H, et al. Retroviral vector-mediated overexpression of the RIII3 subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts. Cell Growth Differ 1994 ; 5 : 753-759
49. Nesterova M, Yokozaki H, McDuffie E, Cho-Chung YS. Overexpression of RII β regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII β. Eur J Biochem 1996 ; 235 : 486-494
50. Bossis I, Stratakis CA. PRKAR1A: normal and abnormal functions. Endocrinology 2004 ; 145 : 5452-5458
51. Neary CL, Nesterova M, Cho-Chung YS, et al. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 2004 ; 23 : 8847-8856
52. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann NY Acad Sci 2005 ; 1058 : 76-86
53. Bourdeau I, Matyakhina L, Stergiopoulos SG, et al. 17q22-24 chromosomal losses and alterations of protein kinase A subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2006 ; 91 : 3626-3632
54. Bossis IA Voutetakis A, Matyakhina L, et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004 ; 41 : 596-600
55. Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A. and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003 ; 63 : 5308-5319
56. Kirschner LS, Sandrini F, Monbo J, et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A. gene in patients with the Carney complex. Hum Mol Genet 2000 ; 9 : 3037-3046
57. Nadella KS, Kirschner LS. Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins. Cancer Res 2005 ; 65 : 10307-10315
58. Mavrakis M, Lippincott-Schwartz J, Stratakis CA, et al. Depletion of type IA regulatory subunit (RI α) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic defi ciency. Hum Mol Genet 2006 ; 15 : 2962-2971
59. Tortora G, Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann NY Acad Sci 2002 ; 968 : 139-147
60. Wu KJ, Mattioli M, Morse HC 3rd, et al. c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-C β) gene. Oncogene 2002 ; 21 : 7872-7882
61. Schwede F, Maronde E, Genieser H, et al. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 2000 ; 87 (2-3): 199-226
62. Tagliaferri P, Clair T, Debortoli ME, et al. Two classes of cAMP analogs synergistically inhibit p21 ras protein synthesis and phenotypic transformation of NIH/3T3 cells transfected with Ha-MuSV DNA. Biochem Biophys Res Commun 1985 ; 130 : 1193-1200 •• Studies [62-65] first showed that site-selective cAMP analogues provide a new physiological means to control the growth of human cancer cells.
63. Tortora G, Tagliaferri P, Clair T, et al. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. Blood 1988 ; 71 (1): 230-233 •• Studies [62-65] first showed that site-selective cAMP analogues provide a new physiological means to control the growth of human cancer cells.
64. Tagliaferri P, Katsaros D, Clair T, et al. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J Biol Chem 1988 ; 263 1: 409-416 •• Studies [62-65] first showed that site-selective cAMP analogues provide a new physiological means to control the growth of human cancer cells.
65. Tagliaferri P, Katsaros D, Clair T, et al. Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues. Cancer Res 1988 ; 48 (6): 1642-1650 •• Studies [62-65] first showed that site-selective cAMP analogues provide a new physiological means to control the growth of human cancer cells.
66. Rohlff C, Clair T, Cho-Chung YS. 8-Cl-cAMP induces truncation and down-regulation of the RI α subunit and up-regulation of the RII β subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 1993 ; 268 : 5774-5782
67. Noguchi K, Murata T, Cho-Chung YS. 8-Chloradenosine 3?,5? -monophosphate (8-Cl cAMP) selectively eliminates protein kinase A type I to induce growth inhibition in c-ras.-transformed fibroblasts. Eur J Cancer 1998 ; 34 : 1260-1267
68. Yokozaki H, Budillon A, Tortora G, et al. An antisense oligodeoxynucleotide that depletes RI α subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993 ; 53 (4): 868-872 •• This paper provided evidence that RI alpha is a growth-inducing protein that may be essential for neoplastic cell growth. Human colon, breast, gastric carcinoma and neuroblastoma cell lines exposed to RI alpha antisense exhibited growth inhibition with no sign of cytotoxicity.
69. Nesterova M, Noguchi K, Park YG, et al. Compensatory stabilization of RII β protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RI α protein. Clin Cancer Res 2000 ; 6 (9): 3434-3441
70. Nesterova M, Cho-Chung YS. A single-injection protein kinase A-directed antisense treatment toainhibit tumour growth. Nat Med 1995 ; 1 (6): 528-533
71. Cho-Chung YS, Nesterova M, Pepe S, et al. Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front Biosci 1999 ; 4 : D898 -907
72. Wang H, Cai Q, Zeng X, et al. Antitumor activity and pharmacokinetics of a mixed-backbone oligonucleotide targeted to the RI α subunit of protein kinase A following oral administration. Proc Natl Acad Sci USA 1999; 96: 13989-13994
73. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RI α subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 2002 ; 21 (1): 73-80
74. Tortora G, Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann NY Acad Sci 2003 ; 1002 : 236-243
75. Mani S, Goel S, Nesterova M, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann NY Acad Sci 2003; 1002 : 252-262
76. Goel S, Desai K, Macapinlac M, et al. A phase I safety and dose escalation trial of docetaxel combined with GEM ® 231, a second generation antisense oligonucleotide targeting protein kinase A R1 α in patients with advanced solid cancers. Invest New Drugs 2006 ; 24 (2): 125-134
77. Madhusudan , Akamine P, Xuong NH, Taylor SS. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat Struct Biol 2002 ; 9 : 273-277
78. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase, Science 2000 ; 289 : 1938-1942
79. Taylor SS, Kim C, Cheng CY, et al. Signaling through cAMP and cAMP-dependent protein kinase: Diverse strategies for drug design. Biochim Biophys Acta 2008 ; 1784 (1): 16-26
80. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specifi c therapeutic agents. Pharmacol Ther 2006 ; 109 : 366-398
81. Iwatsubo K, Okumura S, Ishikawa Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 2006 ; 6 (3): 239-247
82. Pinto C, Papa D, Hübner M, et al. Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J Pharmacol Exp Ther 2008 ; 325 (1): 27-36
83. El-Mowafy AM, Alkhalaf M. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 2003 ; 24 (5): 869-873
84. Naviglio S, Spina A, Chiosi E, et al. Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathway. J Cell Biochem 2006 ; 98 (6): 1584-1596
85. Cho YS, Park YG, Lee YN, et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking C α and RII β subunit overexpression. Proc Natl Acad SciaUSA 2000 ; 97 : 835-840
86. Cvijic ME, Kita T, Shih W, et al. Extracellular catalytic subunit activity of the cAMP dependent protein kinase in prostate cancer. Clin Cancer Res 2000 ; 6 : 2309-2317
87. Kita T, Goydos J, Reitman E, et al. Extracellular cAMP dependent protein kinase (ECPKA) in melanoma. Cancer Lett 2004 ; 208 : 187-191 • The catalytic kinase subunit of the cAMP-dependent protein kinase is secreted by tumor cells and can be detected in the serum of cancer patients. This report examines the clinical signifi cance of this secreted C subunit kinase termed extracellular protein kinase (ECPKA) in melanoma patients. The results showed that the presence of ECPKA activity in the serum of melanoma patients correlates with the appearance and size of the tumor. Most importantly, surgical removal of melanoma caused a precipitous decrease in ECPKA activity in the sera of patients, suggesting that ECPKA may be a novel predictive marker for melanoma.
88. Nesterova MV, Johnson N, Cheadle C, et al. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 2006 ; 66 (18): 8971-8974
89. Wang H, Li M, Lin W, et al. Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev 2007; 16 (4): 789-795